SAMSUNG-BIOEPIS
27.9.2018 01:02:06 CEST | Business Wire | Press release
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k) pathway for SB5, a biosimilar candidate referencing HUMIRA® i (adalimumab). The BLA for SB5 was submitted by Samsung Bioepis in July 2018.
The BLA for SB5 was based on data derived from a randomized, double-blind 52-week Phase 3 study, in which 544 patients with moderate to severe rheumatoid arthritis despite methotrexate (MTX) therapy were randomized to receive either SB5 or the adalimumab reference product (ADL). At Week 24, the ACR20 response rate was 72.4% in the SB5 group versus 72.2% in the ADL group. The safety profile of SB5 was comparable to ADL up to Week 24. At Week 24, 254 patients receiving ADL were re-randomized in a 1:1 ratio to continue on ADL or transitioned to SB5, and 254 patients receiving SB5 continued to receive SB5. Up to Week 52, the efficacy, safety and immunogenicity profiles remained comparable between all three treatment groups. There were no treatment emergent issues or clinically relevant immunogenicity precipitated by alternating subjects between treatments.
Outside of the United States, SB5 has so far received regulatory approval from the European Commission, Korea's Ministry of Food and Drug Safety, Australia's Therapeutic Goods Administration and Health Canada.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
i Humira® is a registered trademark of AbbVie Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926006096/en/
Contact:
MEDIA CONTACT: Samsung Bioepis Co., Ltd. Mingi Hyun +82-31-8061-1594 mingi.hyun@samsung.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grid Dynamics Appoints Industry Veteran Nikita Ivanov as Head of AI26.8.2026 22:05:00 CEST | Press release
Key Takeaways: As Vice President, Head of AI, Nikita Ivanov leads the strategic direction of Grid Dynamics' AI portfolio, including its GAIN platforms, and helps clients convert AI pilots into measurable value in production. Ivanov has over two decades of founding and scaling technology companies as an entrepreneur and technologist, adding commercial and operational depth to Grid Dynamics' executive team. Focused on moving Fortune 1000 clients to AI-native software delivery, Ivanov is advancing Grid Dynamics' AI-SDLC tools that give enterprises a faster, more reliable path to building and running AI systems. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, is advancing its AI strategy under the leadership of Nikita Ivanov, Vice President, Head of AI. Ivanov is responsible for leading the transition efforts of Grid Dynamics’ clients toward an AI-native software delivery model, and he oversees all elements of Grid Dy
Arc'teryx Introduces System 0™, a New Framework for the Future of Product Design and Circularity26.8.2026 15:00:00 CEST | Press release
Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026 Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today introduced System 0™, a new framework that reimagines how products can be designed, manufactured, used, repaired, and ultimately regenerated. System 0 represents the next evolution for sustainability in the outdoor industry, as it embeds circular thinking across an entire product lifecycle while maintaining the uncompromising performance standards that define the Arc’teryx brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826686539/en/ Arc’teryx athlete, Craig Murray, wearing the Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026. The first product being introduced as part of the System 0 platform is the Sperro SV jacket, a
Xsolla Announces Five-Year Partnership With the Global Esports Federation26.8.2026 15:00:00 CEST | Press release
Partnership Represents a Structural Shift in Esports, Placing Xsolla's Infrastructure Behind GEF’s Entire Ecosystem, Spanning Commerce, Payments, Wallet, Loyalty, and Distribution Across Global Esports Games, Global Esports Tour, and 180+ Member Federations Xsolla, a global commerce company, today announced a landmark five-year strategic partnership with the Global Esports Federation (GEF), the world-convening body for esports. As GEF's exclusive partner for commerce, payments, wallet, loyalty, and distribution, Xsolla will power the entire GEF ecosystem, including the flagship Global Esports Games, pro-series Global Esports Tour, global GEFcon, and 180+ Member Federations across five continents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826948844/en/ Graphic: Xsolla The announcement comes as GEF marks 100 days to go to the Los Angeles 2026 Global Esports Games (GEGLA26), adding further momentum to the road to Los An
NABEP Appoints Sara Chouraqui as General Counsel26.8.2026 15:00:00 CEST | Press release
Company expands legal team as it prepares for significant growth North American Blue Energy Partners (NABEP) has appointed Sara Chouraqui as General Counsel, with Elizabeth Collery and Victoria Jacobson each joining as Deputy General Counsel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826168543/en/ Sara Chouraqui joins NABEP as its General Counsel, bringing decades of legal expertise. These additions significantly strengthen NABEP’s senior leadership team and legal expertise as the company improves its operations, increases production and develops new strategic and commercial partnerships. As General Counsel, Chouraqui will lead NABEP’s global legal function and advise the company’s leadership on its legal, regulatory and corporate priorities, including major transactions and partnerships, governance, compliance and the management of legal and regulatory risk across the company’s operations. Her experience navigating
Grafana Labs Crosses 10,000-Customer Milestone as AI Adoption Accelerates Growth Across the Platform26.8.2026 15:00:00 CEST | Press release
Grafana Labs was recently recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, launched six AI-native products during its inaugural AI Week, and surpassed $600M in Annual Recurring Revenue. Grafana Labs, the company behind the open observability cloud, today announced it has crossed 10,000 customers worldwide and surpassed $600 million in annual recurring revenue, as organizations standardize on open observability for the AI era. Teams need AI to help them understand their own systems faster, especially as complexity and overhead remain the top observability concern cited in Grafana Labs' 2026 Observability Survey – a need reflected by the adoption of Grafana Assistant, Grafana Cloud's context-aware AI agent for exploring and troubleshooting observability data, now used by more than 18,000 organizations. Teams also need observability purpose-built for AI systems themselves: When teams move AI into production, models dri
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom